JP2014514927A - 抗原特異的ｔ細胞の増殖のための方法 - Google Patents

抗原特異的ｔ細胞の増殖のための方法 Download PDF

Info

Publication number
JP2014514927A
JP2014514927A JP2014504319A JP2014504319A JP2014514927A JP 2014514927 A JP2014514927 A JP 2014514927A JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014514927 A JP2014514927 A JP 2014514927A
Authority
JP
Japan
Prior art keywords
cells
antigen
specific
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514927A5 (cg-RX-API-DMAC7.html
Inventor
カールソン−パラ，アレックス
ワルグレン，アンナ−カリン
アンデション，ベント
Original Assignee
イミュニカム・エイビイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュニカム・エイビイ filed Critical イミュニカム・エイビイ
Publication of JP2014514927A publication Critical patent/JP2014514927A/ja
Publication of JP2014514927A5 publication Critical patent/JP2014514927A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014504319A 2011-04-13 2012-04-12 抗原特異的ｔ細胞の増殖のための方法 Pending JP2014514927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474904P 2011-04-13 2011-04-13
US61/474,904 2011-04-13
PCT/EP2012/056661 WO2012140130A1 (en) 2011-04-13 2012-04-12 Method for proliferation of antigen-specific t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017049576A Division JP6207783B2 (ja) 2011-04-13 2017-03-15 抗原特異的ｔ細胞の増殖のための方法

Publications (2)

Publication Number Publication Date
JP2014514927A true JP2014514927A (ja) 2014-06-26
JP2014514927A5 JP2014514927A5 (cg-RX-API-DMAC7.html) 2015-05-07

Family

ID=45937382

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014504319A Pending JP2014514927A (ja) 2011-04-13 2012-04-12 抗原特異的ｔ細胞の増殖のための方法
JP2017049576A Expired - Fee Related JP6207783B2 (ja) 2011-04-13 2017-03-15 抗原特異的ｔ細胞の増殖のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017049576A Expired - Fee Related JP6207783B2 (ja) 2011-04-13 2017-03-15 抗原特異的ｔ細胞の増殖のための方法

Country Status (6)

Country Link
US (2) US9476028B2 (cg-RX-API-DMAC7.html)
EP (1) EP2697367B1 (cg-RX-API-DMAC7.html)
JP (2) JP2014514927A (cg-RX-API-DMAC7.html)
KR (1) KR102028340B1 (cg-RX-API-DMAC7.html)
CN (1) CN103502439B (cg-RX-API-DMAC7.html)
WO (1) WO2012140130A1 (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018042481A (ja) * 2016-09-13 2018-03-22 テラ株式会社 抗原特異的ｔ細胞含有組成物及びその製造方法
JP2018521122A (ja) * 2015-06-12 2018-08-02 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 操作されたｔ細胞を用いて癌を処置するための方法
JP2019500045A (ja) * 2015-12-30 2019-01-10 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
JP2019500881A (ja) * 2016-01-08 2019-01-17 プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 老年ｃａｒ−ｔ細胞およびその使用
JP2021000117A (ja) * 2014-04-10 2021-01-07 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP2022081490A (ja) * 2016-06-27 2022-05-31 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
JP2022539249A (ja) * 2019-07-05 2022-09-07 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
US12391921B2 (en) 2016-04-15 2025-08-19 Kyoto University Method for inducing antigen specific CD8 positive T cells

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
DK2913394T3 (en) * 2012-12-18 2016-09-19 Immunicum Ab CO-DIFFERENTIZING AND ENABLING MONOCYTES FROM ALLOGEN DONORS TO PROVIDE PRO-INFLAMMATORY DENDRITIC CELLS
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014186469A2 (en) * 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
EP3154350B1 (en) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
SMT202000203T1 (it) 2014-04-25 2020-05-08 Bluebird Bio Inc Recettori antigenici chimerici con promotore mnd
DK3134095T3 (da) * 2014-04-25 2020-06-29 Bluebird Bio Inc Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
SG11201610170SA (en) 2014-06-06 2017-01-27 Bluebird Bio Inc Improved t cell compositions
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
AU2015339402B2 (en) * 2014-10-27 2021-08-26 Fred Hutchinson Cancer Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
CN104593325A (zh) * 2014-12-09 2015-05-06 深圳源正细胞医疗技术有限公司 诱导dc成熟并分泌高浓度促炎因子的方法
HUE056074T2 (hu) 2014-12-12 2022-01-28 2Seventy Bio Inc BCMA kiméra antigénreceptorok
AU2016258845B2 (en) * 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EP3291821A4 (en) * 2015-05-07 2019-03-20 Baylor College of Medicine IMMUNOTHERAPY WITH DENDRITIC CELLS
JP6816026B2 (ja) * 2015-05-13 2021-01-20 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
WO2017024006A1 (en) * 2015-08-03 2017-02-09 The Johns Hopkins University Personalized, allogeneic cell therapy of cancer
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
KR102770425B1 (ko) * 2016-02-08 2025-02-18 고쿠리츠다이가쿠호진 미에다이가쿠 면역체크포인트 저해제 저항성 종양에 대한 t세포 수주요법의 전처치약
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN107779433A (zh) * 2016-08-30 2018-03-09 天津市康婷生物工程有限公司 便捷的刺激nk细胞增殖和分化的饲养层制备方法
KR20190066073A (ko) 2016-10-26 2019-06-12 이오반스 바이오테라퓨틱스, 인크. 냉동보존된 종양 침윤 림프구의 재자극
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46723A (fr) 2016-11-04 2019-09-11 Bluebird Bio Inc Compositions de lymphocytes t car anti-bcma
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
CA3045338A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
US11357841B2 (en) 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
KR20240059648A (ko) 2017-04-19 2024-05-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
CN107502589A (zh) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
US12104172B2 (en) 2018-01-08 2024-10-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific t-cells
CN112055595B (zh) 2018-01-22 2024-12-17 恩多塞特公司 Car t细胞的使用方法
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN108841792A (zh) * 2018-06-14 2018-11-20 浙江大学 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
CN109370987A (zh) * 2018-11-23 2019-02-22 见多视光(北京)科技有限公司 外周血ctl细胞改良的培养方法
WO2020243561A1 (en) * 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
JP2023519346A (ja) * 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
CA3182607A1 (en) 2020-06-30 2022-01-06 Erik Hans MANTING Use of leukemia-derived cells in ovarian cancer vaccines
CN113234674B (zh) * 2021-03-15 2023-02-07 青岛华赛伯曼医学细胞生物有限公司 一种t细胞活化扩增的方法及其应用
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
CN115068598A (zh) * 2022-04-25 2022-09-20 福建医科大学孟超肝胆医院(福州市传染病医院) Tlr激动剂以及包含新生抗原的免疫原性组合物在制备药物中的应用
WO2025212473A1 (en) * 2024-04-01 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to identify and selectively expand tumor antigen-specific t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521406A (ja) * 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
US9211321B2 (en) * 2009-10-27 2015-12-15 Immunicum Ab Method for proliferation of antigen-specific T cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521406A (ja) * 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5014006076; ＹＡＮＧ　ＳＨＩＣＨＥＮＧ: 'Ａ　ＳＩＭＰＬＩＦＩＥＤ　ＭＥＴＨＯＤ　ＦＯＲ　ＴＨＥ　ＣＬＩＮＩＣＡＬ-ＳＣＡＬＥ　ＧＥＮＥＲＡＴＩＯＮ　ＯＦ　ＣＥＮＴＲＡＬ　ＭＥＭＯＲＹ-ＬＩＫＥ　ＣＤ８＋　Ｔ　ＣＥＬＬＳ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ３３　Ｎ６, 20100701, Ｐ６４８-６５８ *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021000117A (ja) * 2014-04-10 2021-01-07 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP7508516B2 (ja) 2014-04-10 2024-07-01 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP2022184989A (ja) * 2014-04-10 2022-12-13 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 特定の組成を有する遺伝子により改変されたｔ細胞製剤
JP7148580B2 (ja) 2014-04-10 2022-10-05 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 特定の組成を有する遺伝子により改変されたｔ細胞製剤
US10639329B2 (en) 2015-06-12 2020-05-05 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
JP2018521122A (ja) * 2015-06-12 2018-08-02 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 操作されたｔ細胞を用いて癌を処置するための方法
US12193995B2 (en) 2015-06-12 2025-01-14 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
JP7019578B2 (ja) 2015-12-30 2022-02-15 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
JP2019500045A (ja) * 2015-12-30 2019-01-10 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
JP2019500881A (ja) * 2016-01-08 2019-01-17 プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 老年ｃａｒ−ｔ細胞およびその使用
US12391921B2 (en) 2016-04-15 2025-08-19 Kyoto University Method for inducing antigen specific CD8 positive T cells
JP2022081490A (ja) * 2016-06-27 2022-05-31 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
JP7340638B2 (ja) 2016-06-27 2023-09-07 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
JP2018042481A (ja) * 2016-09-13 2018-03-22 テラ株式会社 抗原特異的ｔ細胞含有組成物及びその製造方法
JP2022539249A (ja) * 2019-07-05 2022-09-07 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
JP7668781B2 (ja) 2019-07-05 2025-04-25 ケース ウェスタン リザーブ ユニバーシティ 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法

Also Published As

Publication number Publication date
EP2697367B1 (en) 2018-12-19
US20170035870A1 (en) 2017-02-09
US9476028B2 (en) 2016-10-25
KR20140052991A (ko) 2014-05-07
CN103502439A (zh) 2014-01-08
WO2012140130A1 (en) 2012-10-18
JP2017127314A (ja) 2017-07-27
JP6207783B2 (ja) 2017-10-04
EP2697367A1 (en) 2014-02-19
CN103502439B (zh) 2016-10-12
US20140112956A1 (en) 2014-04-24
KR102028340B1 (ko) 2019-10-04
US9789174B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
JP6207783B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
JP5816627B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
JP7452929B2 (ja) 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
US12215136B2 (en) Exosome for stimulating T cell and pharmaceutical use thereof
JP5779090B2 (ja) 新規に単離された細胞の治療組成物の操作および送達
EP2700708A2 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
WO2009114085A2 (en) Allogeneic cancer cell-based immunotherapy
AU2016219379A1 (en) Chlamydia-activated B cell platforms and methods thereof
Rossowska et al. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo
US20160235827A1 (en) Placental compositions for stimulation of immunity to pd-l1
CN101626781A (zh) 制备具有抗肿瘤免疫应答反应的细胞群的方法
Jæhger Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy
HK1168869A1 (en) Method for proliferation of antigen-specific t cells
HK1168869B (en) Method for proliferation of antigen-specific t cells
Zhang Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling
Li et al. Cytokine Modulation Facilitates the In Vitro Generation of Antigen Specific T Cells for Adoptive Immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161115